Literature DB >> 15515778

Validation of the classification criteria commonly used in Korea and a modified set of preliminary criteria for Behçet's disease: a multi-center study.

H K Chang1, S S Lee, H J Bai, Y W Lee, B Y Yoon, C H Lee, Y H Lee, G G Song, W T Chung, S W Lee, J Y Choe, C G Kim, D K Chang.   

Abstract

OBJECTIVE: Recently we have proposed a modified set of criteria to settle the questions raised regarding the International Study Group (ISG) criteria for Behçet's disease (BD). The aim of the present study was to validate the two pre-existing criteria sets commonly used in Korea, the ISG criteria and the criteria of the Behçet's Disease Research Committee of Japan (Japanese criteria), as well as the proposed modified criteria.
METHODS: The study population included 155 consecutive patients with BD and 170 controls with non-Behçet's rheumatic diseases. Detailed data for all of the subjects were recorded prospectively by the participating physicians on a standard form that listed the clinical features of BD. The sensitivity, specificity, and accuracy of each set of the criteria were measured.
RESULTS: Of the three criteria sets employed, the modified criteria were the most accurate, with an accuracy of 96.3%. The ISG criteria often failed to classify the following patients with BD: patients with only oral and genital ulcerations, certain patients with intestinal ulcerations, patients who did not manifest oral ulcerations, and patients with acute disease but fewer than three recurrent oral ulceration relapses in a 1-year period. The Japanese criteria also failed to categorize the following patients with BD: patients with oral and genital ulcerations, and patients with oral ulcerations, skin lesions, and a positive pathergy reaction. In addition, the Japanese criteria misclassified some of the control subjects with non-Behçet's uveitis as having BD.
CONCLUSIONS: The results of this study suggest that there are some points that need to be reconsidered in the clinical application of the two pre-existing sets of criteria. Although the modified criteria were the most accurate, further validation studies will be required in other ethnic populations.

Entities:  

Mesh:

Year:  2004        PMID: 15515778

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

Review 1.  Diagnostic/classification criteria in pediatric Behçet's disease.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-11-14       Impact factor: 2.631

2.  Validation of the revised International Criteria for Behcet's Disease (ICBD) in Iran.

Authors:  Fereydoun Davatchi; Bahar Sadeghi Abdollahi; Cheyda Chams-Davatchi; Farhad Shahram; Abdolhadi Nadji; Hormoz Shams; Tahereh Faezi; Massoomeh Akhlaghi; Farimah Ashofteh; Maryam Mataji; Kamran Moradi; Negin Mohtasham
Journal:  Clin Rheumatol       Date:  2013-10-23       Impact factor: 2.980

3.  Neurological manifestations of Behçet's disease in Japan: a study of 54 patients.

Authors:  Haruko Ideguchi; Akiko Suda; Mitsuhiro Takeno; Yohei Kirino; Atsushi Ihata; Atsuhisa Ueda; Shigeru Ohno; Yasuhisa Baba; Yoshiyuki Kuroiwa; Yoshiaki Ishigatsubo
Journal:  J Neurol       Date:  2010-02-03       Impact factor: 4.849

4.  Clinical characteristics of Behçet's disease in China.

Authors:  Liao-Yuan Wang; Dong-Bao Zhao; Jun Gu; Sheng-Ming Dai
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

5.  Diagnosis/Classification Criteria for Behcet's Disease.

Authors:  Fereydoun Davatchi
Journal:  Patholog Res Int       Date:  2011-09-27

6.  Analysis of diagnostic criteria in adamantiades-behçet disease: a retrospective study.

Authors:  Nicola di Meo; S Bergamo; P Vidimari; S Bonin; G Trevisan
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494

7.  Meta-analysis of anti-Saccharomyces cerevisiae antibodies as diagnostic markers of Behçet's disease with gastrointestinal involvement.

Authors:  Linlin Cheng; Liubing Li; Chenxi Liu; Songxin Yan; Yongzhe Li
Journal:  BMJ Open       Date:  2020-10-06       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.